Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway
- 15 Downloads
Carfilzomib (CFZ), a proteasome inhibitor approved by the FDA to treat multiple myeloma, may cause nephrotoxicity.
Rutin is a bioflavonoid with antioxidant properties. We aimed to examine whether rutin protects the kidney from CFZ-induced nephrotoxicity.
This study aimed to demonstrate the effect of rutin on CFZ-induced renal injury via the inhibition of oxidative stress and inflammation.
Wistar albino rats were divided into six groups (n = 6): Group 1 (normal control; NC) was administered normal saline for 3 weeks; Group 2 (CFZ/toxic group) received CFZ [4 mg/kg, intraperitoneal (i.p.) injection] twice weekly for 3 weeks; Group 3 (standard treatment group) was administered CFZ (4 mg/kg, i.p.) and olmesartan (2 mg/kg, p.o.) for 3 weeks; Group 4 was administered CFZ (4 mg/kg, i.p.) and rutin (10 mg/kg, p.o.) for 3 weeks; Group 5 was administered CFZ (4 mg/kg, i.p.) and rutin (20 mg/kg, p.o.) for 3 weeks; and Group 6 was administered CFZ (4 mg/kg, i.p.) and rutin (40 mg/kg, p.o.) for 3 weeks. We carried out haematological and biochemical analyses, determined oxidative stress, caspase-3 activity, and protein levels, and performed a histopathological evaluation to confirm CFZ-induced nephrotoxicity and its prevention by rutin administration.
Exposure to only CFZ significantly (p < 0.05) increased white blood cell (WBC) count, Hb%, and HTC% concentration; however, these features were significantly decreased (p < 0.05) when olmesartan and rutin were administered. CFZ administration significantly decreased (p < 0.0001) the level of antioxidant enzymes; whereas, administration of olmesartan and rutin significantly reversed (p < 0.05) their levels toward the normal range. The levels of caspase-3 enzyme significantly increased (p < 0.001) in the CFZ group and were reduced toward the normal values by olmesartan and rutin administration. Furthermore, the results of NOS-2, NF-κB, IkBa, and IL-17 protein estimation and the histopathological evaluation strengthened our findings that rutin exhibits a protective effect against CFZ-induced nephrotoxicity.
These findings clearly demonstrate that rutin ameliorates CFZ-induced oxidative stress and inflammation in nephrotoxicity via the NOS-mediated NF-κB signaling pathway.
KeywordsRutin Carfilzomib Nephrotoxicity NOS-2 NF-κB Histopathology
Analysis of variance
Blood urea nitrogen
Food and Drug Application
Glomerular filtration rate
Hematoxylin and eosin
Inhibitory kappa-B alpha
Nicotinamide adenine dinucleotide phosphate
Nuclear factor kappa-B
Nitric oxide synthase
Red blood cells
Ras homolog gene family, member A
Rho-associated kinase (rho-kinase)
Standard error of mean
Transforming growth factors
White blood cells
The present work was funded by King Saud University, Deanship of Scientific Research, College of Pharmacy (project no. RGP-VPP-305). The authors would like to thank the Department of Pharmacology and Toxicology at the College of Pharmacy, King Saud University for granting us permission to use its facilities.
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
- Altinterim B (2014) Citrus, rutin and on their vein permeability effects. RJAEM 3:80–81Google Scholar
- Claiborne A (1985) Catalase activity. In: Greenwald RA (ed) CRC handbook of methods for oxygen radical research. CRC Press Inc, Boca Raton, pp 283–284Google Scholar
- Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK (2007) Antitumor activity of PR171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383–6391CrossRefGoogle Scholar
- Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L et al (2003) Characterization of hepatic cytochrome P 450 3A activity in patients with end-stage renal disease. J Clin Exp Pharmacol 73:427–434Google Scholar
- Heather S, Demrow BS, Peter R, Slane BS, John DF (1995) Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Am Heart Assoc 91:1182–1188Google Scholar
- Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, Palmby TR, Jee J, Adams W, Mahayni H, Brown J, Dorantes A, Sridhara R, Farrell AT, Pazdur R (2013) Food and drug administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 19(17):4559–4563CrossRefGoogle Scholar
- Imam F, Al-Harbi NO, Al-Harbi MM, Ansari MA, Almutairi MM, Alshammari M, Almukhlafi TS, Ansari MN, Aljerian K, Ahmad SF (2016) Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats. Toxicol Mech Methods 26:700–708CrossRefGoogle Scholar
- Imam F, Al-Harbi NO, Al-Harbi MM, Korashy HM, Ansari MA, Sayed-Ahmed MM, Nagi MN, Iqbal M, Khalid Anwer M, Kazmi I, Afzal M, Bahashwan S (2017) Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-κB, hypertrophic gene expression and oxidative stress. Cardiovasc Toxicol 17:58–66CrossRefGoogle Scholar
- McBride L, Samuel CO (2013) The side effect profile of carfilzomib: from clinical trials to clinical practice. J Adv Pract Oncol 4:22–30Google Scholar
- Nooka AK (2013) Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park) 27:11–18Google Scholar
- Sahu BD, Tatireddy S, Koneru M, Borkar RM, Jerald MK, Kuncha M, Srinivas R, Shyam Sunder R, Sistla R (2014) Naringin ameliorates gentamicin-induced nephrotoxicity and associated mitochondrial dysfunction, apoptosis and inflammation in rats: possible mechanism of nephroprotection. Toxicol Appl Pharmacol 277:8–20CrossRefGoogle Scholar
- Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M (2012) An openlabel, singlearm, phase 2 study of single agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158:739–748CrossRefGoogle Scholar